论文部分内容阅读
近十多年来,关于急性髓系白血病(acute myeloid leukemia,AML)的研究无论在机制探讨、临床治疗及残余肿瘤细胞的随访检测方面都有了显著进展。本文将就此作一简单介绍。基因诊断AML是一类以造血干细胞分化受损、克隆性增殖、原始粒细胞大量聚积的一组异质性疾病。在过去的十多年中,细胞遗传学改变和分子生物学的特征已构成了AML预后分组——低危和中高危的
For more than a decade, research on acute myeloid leukemia (AML) has made remarkable progress in mechanism exploration, clinical treatment and follow-up detection of residual tumor cells. This article will make a brief introduction to this. Genetic Diagnosis AML is a group of heterogeneous diseases characterized by impaired differentiation of hematopoietic stem cells, clonogenic proliferation, and massive accumulation of primitive granulocytes. Over the past decade or so, the characteristics of cytogenetics and molecular biology have constituted the AML prognosis group - low-risk and middle-high-risk